Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial
Alistair Ring(National Health Service), Jack Cuzick(Queen Mary University of London), Mitch Dowsett(Institute of Cancer Research), Anthony Howell(Breast Cancer Care), John Forbes(University of Limerick), Aman U. Buzdar(The University of Texas MD Anderson Cancer Center), Ivana Šestak(Cancer Research UK), Michael Baum(International Center for Agricultural Research in the Dry Areas)
Cited by 58
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Overview of the European and North American studies on HPV testing in primary cervical cancer screening
|International Journal of Cancer|2006|1.1k